In this paper, we will present a model of cancer tumor growth that describes the interaction between an oncolytic virus and tumor cells. This is a tree-population model that includes uninfected cells, tumor cells, and the oncolytic virus. We give the basic reproduction number R 0 and we show that there exists a disease free equilibrium points (DFE) and an endemic equilibrium point (DEE). Using a Lyapunov function, we prove that the DFE is globally asymptotically stable if R 0 < 1 and unstable otherwise. We also prove that under an additional condition, the DEE is stable when R 0 > 1. To illustrate our results numerical simulations are also presented.
Introduction
Cancer represents a real crisis for public health and health systems worldwide. It is predicted to be an increasingly important cause of morbidity and mortality in the next few decades, in all regions of the world. The International Agency for Research on Cancer (IARC) estimated that for the year 2008 there were 12.7 million incident cases of cancer, 7.6 million deaths from cancer and 28 million persons alive with cancer within five years from initial diagnosis. IARC also estimated that just over half of incident cases and two thirds of cancer deaths arise in low-and medium-income countries [1] . The forecasted changes in population demographics in the next two decades mean that even if current global cancer rates remain unchanged, the estimated incidence of new cancer cases in 2008 will rise to 22 million by 2030 [2] .
Treatments traditionally used to fight against cancer are surgery, radiotherapy and chemotherapy. But despite advances in developing treatments for cancer in the last decade, patients with certain forms of cancer are still left with limited options for therapy. Many tumors also remain completely incurable, creating a need for a broader spectrum of therapeutic strategies. One promising form of treatment is oncolytic virotherapy.
Oncolytic virotherapy consists of the use of replication-competent viruses to infect and kill tumor cells preferentially, without damaging healthy cells. The idea that viruses may be able to eradicate cancer dates back to the early 20th century, but, for several years, research in this field was limited due to technological limitations. Now, as genetic engineering has advanced so enormously and rapidly, it has revived interest in oncolytic virotherapy. An increased understanding of virology, as well as experience using viruses in cancer gene therapy, has prompted a new wave of oncolytic virotherapy. (For the history of oncolytic viruses, see [3] [4] ). Oncolytic viruses (viruses that selectively infect and replicate in tumor cells, but spare normal cells) have two types: oncolytic wild viruses that naturally occur with preferential in human cancer cells, and gene-modified viruses engineered to achieve selective oncolysis. There are many oncolytic viruses which have demonstrated anti-tumor efficacy, including adenoviruses, Coxsackieviruses, herpes simplex viruses, measles viruses and Newcastle disease virus. Additionally, a wide array of viruses is being tested for potential as oncolytic viruses. (For a partial list of oncolytic viruses, see [5-6-7] )
Mathematical modelling of cancer treatment has increasingly become a tool to study the underlying dynamics of therapy systems. In the context of oncolytic virotherapy, extensive efforts have been dedicated over many years to the development of several models that can help to understand this emerging treatment, to interpret experimental results, and to design efficient protocols. In the literature, a wide variety of virotherapy models have been proposed. The first mathematical models of oncolytic virus therapy considered ordinary differential equations that described the basic interactions between two types of tumor cells (the cells that are infected by the virus and the cells that are not infected but are susceptible to the virus so far as they have the cancer phenotype) and the immune system [8] [9] . Other works consider spatial representation of tumors [10-11-12] , multi-scale effects [13] and stochastic processes [14] . For a review of different mathematical modeling approaches ranging from ordinary differential equations to spatially explicit agent-based models, see [15] .
In this work, we will give a rigorous mathematical study of an oncolytic virotherapy model based on the models proposed by [16] and [17] . This paper is organized as follows. In section 2,we will present our mathematical model. In section 3, we will give some properties of solutions. The analysis of the model is presented in section 4. Finally, a discussion and conclusion are given in section 5.
Mathematical model
In this work, we consider the model presented by [16] with the burst size of a virus (the number of new viruses released from a lysis of an infected cell) as introduced in [17] . This model contains three variables, which are, uninfected tumor cell population x(t), infected tumor cell population y(t) and free virus particles which are outside cells v(t). The model is given by the following nonlinear system of differential equations
where x(0) = x 0 , y(0) = y 0 and v(0) = v 0 are given.
The term rx 1 − x + y k describes the logistic growth rate of an uninfected tumor cell population x(t). The constant r > 0 is the growth rate constant, while K is the carrying capacity or maximal tumor size so that x + y ≤ K. The term βxv represents the rate of inefcted cells by free virus v(t), with β > 0 being the corresponding rate constant.The term ρxy models infection from an encounter between an infected cell and an uninfected cell resulting in cell fusion that produces a syncytium, with ρ > 0 is the rate constant describing cell to cell fusion with the formation of syncytia. Infected cells die at a rate δy, and γv is the rate of elimination of free virus particles by various causes including non specific binding and generation of defective interfering particles. The virus replication ability is modeled by its burst size. The burst size of a virus is the number of new viruses released from a lysis of an infected cell. The burst size of a virus, the number of new viruses released from a lysis of an infected cell, is an important parameter of virus replicability. So our model includes also a parameter b that models the burst size.
Using the Van Den Driesseche and Watmough next generation approach, we caclcuate the basic infection reproduction number of the systeme (1), which is as follows
Properties of solutions
In this section, we give some properties of solutions of system (1)
Positivity and boundedness of solutions
The model (1) describes the evolution of a cell population. Hence, the cell numbers should remain non negative and bounded.
Proof. See Lemma 3.2 in [17]
Proposition 2 For solutions starting from nonnegative initial conditions, we have
Proof.
-As dx dt
x (t) ≤ x (0) e −rt + K, and since 0 ≤ e −rt ≤ 1, we get i).
-As dv dt = bδy −βxv −γv ≤ bδy −γv ≤ bδK −γv we deduce that, dv dt +γv ≤ bδK.
, and since 0 ≤ e −γt ≤ 1,
we get ii).
-From dy dt = βxv−δy ≤ βKv−δy we deduce that,
, and since 0 ≤ e −δt ≤ 1, we get iii).
Non-periodicity and limiting behavior
Proposition 3 Let X be a solutions of system (1) .If X (0) ∈ R 3 + then the limite of X (t) exists when t −→ +∞,In particular, X is periodic if only if X is stationary. Moreover, we have
To prove this proposition, we need the following lemma 
Proof. Proof of Lemma.4 , see [17] .
Proof. Proof of Proposition 3
-We have x (t) ≤ x (0) e −rt +K (see proof of propositon 2) and since lim t−→+∞ e −rt = 0, we get i).
-Also we have v (t) ≤ bδK γ + v (0) e −γt . Since lim t−→+∞ e −γt = 0, thus ii).
-From dy dt = βxv − δy , and dv dt = bδy − βxv − γv , we have dy dt
Using the integration by parts, we get
Hence, lim sup
Thus, lim sup
Model analysis
In this section, we show the existence of the equilibrium points and we study their stability. Let us define the domain D = {(x, y, v) :
From Proposition 1 and Proposition 3, D is a positive invariant domain for the system (1). It is also a biological meaningful range for variables. We then refer the whole domain D as a "global" domain.The system (1) has three equilibria, E 0 = (0, 0, 0), E 1 = (K, 0, 0), and the positive equilibrium E * (x * , y * , v * ).Where
,
The Jacobian matrix of the system (1 ) at an arbitrary point is given by
It is easy to prove that E 0 is always unstable. For the other equilibrium we have the following results.
Free equilibria
the system always has disease free equilibria of the form E 1 = (K, 0, 0) .
The Jacobian matrix evaluated at
The eigenvalues of the matrix J E 1 are λ 1 = −r, λ 2 = − (βK + γ + δ)− (βK + γ − δ) 2 + 4bδβK and λ 3 = − (βK + γ + δ) + (βK + γ − δ) 2 + 4bδβK. The eigenvalue λ 1 and λ 2 are both negative for all non-negative parameter values, while the eigenvalue λ 3 can be negative, positive and zero.
-Suppose R 0 < 1, then βbk βK + γ < 1. It implies that (βK + γ − δ) 2 + 4bδβK < (βK + γ + δ) 2 . Since βK + γ + δ is positive, we have (βK + γ − δ) + 4bδβK < (βK + γ + δ), then λ 3 is negative. Hence all three eigenvalues are negative. So E 0 is locally asymptotically stable.
-When R 0 > 1, we have (βK + γ − δ) + 4bδβK > (βK + γ + δ) , and λ 3 is positive. Then, E 1 is unstable.
Actually, by using a Lyapunov function, we will prove that the equilibrium point E 1 is globally asymptotically stable when R 0 < 1. Here by the word "globally", we mean the whole positive invariant domain D. For convenience, we make a translation of variables, x = K − x , y = y , and v = v . The system becomes
Theorem 6 If R 0 < 1, E 1 is globally asymptotically stable.
Proof.
For any initial condition (x 0 , y 0 , v 0 ) in the Domain D 1 , we know from proposition 1 and propostion 3, that the solution satisfies 0 ≤ x (t) ≤ K, 0 ≤ y (t) ≤ K and v (t) ≥ 0 and we define a Lyapunov function by V (x, y, v) = (βK + γ) y + βKv It is easy to see V (x, y, v) > 0. The derivative along a solution is given by : V (x, y, v) = (βK + γ)ẏ+βKv = (βK + γ) (βKv − βxv − δy)+βK (bδy + βxv − (βK + γ) v) = δy (βKb − (βK + γ)) + (βK + γ) βKv − βK (βK + γ) v − (βK + γ) βxv + βKβxv = δy (βKb − (βK + γ)) − γβxv < 0 Indeed, when R 0 < 1, we have βKb < βK + γ so βKb − (βK + γ) < 0 and since −γβxv < 0 thenV < 0.
Considering the component x (t), we see that
0 ≤ x (t) ≤ he −rt + e −rs t 0 (Kβv (s) + (r + ρK) y (s)) e rs ds where h is the initial value for x (t)Ṫhe limit he −rt −→ 0 as t −→ +∞, while lim t−→+∞ e −rt t 0 (Kβv (s) + (r + ρK) y (s)) e rs ds ≤ lim sup t−→+∞ t 0 (Kβv (s) + (r + ρK) y (s)) e r(s−t) ds
we have lim sup t−→+∞ (Kβv (t) + (r + ρK) y (t)) = 0 Thus x (t) −→ 0 as t −→ +∞ Such, (x, y, v) approaches the origin wherever the initial value is in D 1 .Therefore, the original system (1) has a global attractor E 1 .
Endemic equilibria
Here we study the stability of the endemic equilibrium points E * .
Theorem 7 If R 0 > 1 and f (b) < rγ + Kργ − Kβδ then E * is locally asymptotically stable where
The Jacobian matrix at E * is given by
The characteristic equation associated with J E * is given by
Where
and a 3 = γrδ (Kβb − Kβ − γ) Kβ (b − 1) By the Routh-Hurwitz Criterion [7] , all roots of the polynominal (4) have negative real parts if and only if 
Numerical simulation
In this section, we will present some numerical results on the dynamics of virotherapy for different values of R 0 .
Since our model considers population of cells, we convert tumor volume to cell population by assuming, as all ODE models do, 1mm
3 corresponds to 10 6 cells. We consider cell and virus populations x,y and v as expressed in units of 10 6 . The goal of cancer virotherapy is to eliminate tumor cells. So, for the model (1), we assume that the tumor is completely eliminated when the total population of tumor cells is reduced to one cell, which means that in the adopted units u(t) = x(t) + y(t) = 10 6 . The numerical simulations were carried out using the following data taken from [16] .r = 0.206, K = 2139, β = 0.001, ρ = 0.2145, δ = 0.5115, and γ = 0.001. Figure 1 shows that for R 0 > 1 the virotherapy success and the treatment will reach the equilibrium point E * . Figure 2 shows that for R 0 < 1 the virotherapy fails as the population of tumor cells increase and the population of infected tumor decrease. 
Conclusion
The work in this paper contributes to a growing literature on modelling oncolytic virotherapy. We consider a mathematical model describing the interaction between an oncolytic virus and tumor cells. We calculate the basic reproduction number R 0 , and we use it to study the stability of the equilibrium states. We prove that the disease free equilibrium is globally asymptotically stable if the basic infection reproduction number R 0 < 1, and when R 0 > 1 the local stability of the endemic equilibrium point depends of function f (b) representing the replication of virus in virotherapy.
In addition, the numerical simulation provides that if R 0 > 1, the number of the uninfected cells decreases, and both the number the infected cells and virus increase after 100 days. The treatment will reach the equilibrium point E * and the tumor is completely eliminated, which prove the success of the virotherapy. However, for R 0 < 1 the virotherapy fails as the population of tumor cells increase and the population of infected tumor decrease.
